Business
Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate
Target Indications include Osteoarthritis and Other Pain Conditions NAPLES, Fla., Feb. 8, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"Target Indications include Osteoarthritis and Other Pain Conditions\nNAPLES, Fla., Feb. 8, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) (\"Enveric\" or the \"Company\"), a neuroscience company developing next-generation, psychedelic-inspired mental health, and oncology treatments, today announced the development of EV104a and EV104b, new molecular conjugates for Osteoarthritis (\"OA\") and other pain indications.\nThe treatment paradigm for OA, as reflected in a recent review \"Future Directions for the Management of Pain in Osteoarthritis\" by Nidhi Sofat, is largely unsatisfactory and based on alleviating pain using NSAIDs and other pharmacotherapies or intra-articular injection of corticosteroids, or hyaluronic acid. Newer therapeutic alternatives, including combination treatments, are needed for optimal control of symptoms. Enveric recently licensed an Innovative Platform technology from Diverse Biotech that led to the successful synthesis of EV104a, and EV104b, two new chemical entity conjugates of cannabidiol (CBD) linked to celecoxib.\nEV104a and EV104b are specifically designed to optimize pharmacokinetics and therapeutic synergy via improved delivery, targeting abilities, and potency to potentially be more efficacious and display fewer side effects than current treatments. Enveric has confirmed the stability of the molecules and the robustness of the manufacturing method. Pre-clinical in vitro testing and characterization of these molecules is underway. This program aims to create a new treatment with improved tolerability, decreased toxicity, fewer side effects, and enhanced long-term efficacy. \nThe EV104 celecoxib-cannabinoid conjugates are protected by a recently filed provisional United States patent application claiming the compositions, methods of synthesis, and methods of treatment for inflammatory medical conditions.\n\"We are pleased to announce the creation of EV104a and EV104b for the potential treatment of OA and other pain indications. Despite available therapies, individuals with OA continue to suffer and look for new treatments to remediate their pain. As the Company moves forward to execute our clinical development plans, we believe our assets have the potential to demonstrate superior efficacy with a more favorable safety profile compared to current standards of treatment,\" said Dr. Joseph T...